Gene therapy injection aims to slow vision loss in rare eye disease
Disease control
Not yet recruiting
This early-stage trial tests a single injection of a gene therapy drug called UGX202 in 6 adults with advanced retinitis pigmentosa, a genetic condition that causes vision loss. The main goal is to check if the treatment is safe and tolerable over 52 weeks. Researchers will also …
Phase: EARLY_PHASE1 • Sponsor: Suzhou UgeneX Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC